Gold nano-particles (AuNPs) carrying anti-EBV-miR-BART7-3p inhibit growth of EBV-positive nasopharyngeal carcinoma

Longmei Cai; Jinbang Li; Xiaona Zhang; Yaoyong Lu; Jianguo Wang; Xiaoming Lyu; Yuxiang Chen; Jinkun Liu; Hongbing Cai; Ying Wang; Xin Li

doi:10.18632/oncotarget.3046

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Gold nano-particles (AuNPs) carrying anti-EBV-miR-BART7-3p inhibit growth of EBV-positive nasopharyngeal carcinoma

Longmei Cai _, Jinbang Li, Xiaona Zhang, Yaoyong Lu, Jianguo Wang, Xiaoming Lyu, Yuxiang Chen, Jinkun Liu, Hongbing Cai, Ying Wang and Xin Li

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:7838-7850. https://doi.org/10.18632/oncotarget.3046

Metrics: PDF 3027 views | HTML 3035 views | ?

Abstract

Longmei Cai1,*, Jinbang Li1,*, Xiaona Zhang1,4,*, Yaoyong Lu1,5,*, Jianguo Wang1, Xiaoming Lyu1,3, Yuxiang Chen1, Jinkun Liu2, Hongbing Cai2, Ying Wang1, Xin Li1

1Cancer Research Institute, Southern Medical University, Guangzhou 510515, China

2School of Chinese Traditional Medicine, Southern Medical University, Guangzhou 510515, China

3Central Medical Laboratory, The Third Affiliated Hospital, Southern Medical University, Guangzhou 510515, China

4The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, China

5Department of Radiation Oncology, Gaozhou People's Hospital, Gaozhou 525200, China

* These authors contributed equally.

Correspondence to:

Xin Li, e-mail: [email protected]

Ying Wang, e-mail: [email protected]

Hongbing Cai, e-mail: [email protected]

Keywords: Nasopharyngeal carcinoma, EBV-miR-BART7, tumorigenesis, therapeutic experiment

Received: September 15, 2014 Accepted: January 07, 2015 Published: February 19, 2015

ABSTRACT

Epstein-Barr virus (EBV) infection is a major etiological factor for nasopharyngeal carcinoma (NPC). Several EBV-encoded BART miRNAs have been associated with viral latency, immune escape, cell survival, cell proliferation and apoptosis. Here, we report that EBV-miR-BART7-3p, an EBV-encoded BART miRNA highly expressed in NPC, was correlated with cell-cycle progression in vitro and increased tumor formation in vivo. This viral miRNA stimulated the PTEN/PI3K/Akt pathway and induced c-Myc and c-Jun. Knockdown of PTEN mimicked EBV-miR-BART7-3p-induced tumorigenic phenotype. Based on these results, we conducted a therapeutic experiment by using gold nano-particles (AuNPs) carrying anti-EBV-miR-BART7-3p. Silencing of EBV-miR-BART7-3p reduced tumor growth in animal model. We conclude that EBV-miR-BART7-3p favors carcinogenesis, representing a potential target for miRNA-based therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3046

Publication Alerts

Research Papers:

Gold nano-particles (AuNPs) carrying anti-EBV-miR-BART7-3p inhibit growth of EBV-positive nasopharyngeal carcinoma

Abstract